Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.
R L
RL
Rosati
P
P
Da Silva Jardine
K O
KO
Cameron
D D
DD
Thompson
H Z
HZ
Ke
S M
SM
Toler
T A
TA
Brown
L C
LC
Pan
C F
CF
Ebbinghaus
A R
AR
Reinhold
N C
NC
Elliott
B N
BN
Newhouse
C M
CM
Tjoa
P M
PM
Sweetnam
M J
MJ
Cole
M W
MW
Arriola
J W
JW
Gauthier
D T
DT
Crawford
D F
DF
Nickerson
C M
CM
Pirie
H
H
Qi
H A
HA
Simmons
G T
GT
Tkalcevic
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000378:metabolism; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000378:metabolism / Q000494:pharmacology; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D010052:Ovariectomy; D011759:Pyrrolidines / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011960:Receptors, Estrogen / Q000819:agonists* / Q000037:antagonists & inhibitors*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014599:Uterus / Q000187:drug effects
D004965:Estrogen Antagonists; D000960:Hypolipidemic Agents; D011759:Pyrrolidines; D011960:Receptors, Estrogen; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene; D004997:Ethinyl Estradiol; D002784:Cholesterol